CellCura has entered into a memorandum of understanding with IDT Biologika to test and adapt its patented protein free media used in the production of human vaccine. The protein free media improves safety and stability in cultivation of cell-lines for manufacturing viral-based vaccines.The agreement is in line with exploring the extended patent application filed by CellCura in April this year and the strategy of creating new business areas based on the company’s in-house proprietary technology.
CellCura CEO Lars Bredahl said that regulatory authorities in most markets, including the EU and the US will favor the use of well defined, protein free media in future vaccine development and manufacturing.
“An extension of the Company’s media technology to include vaccine manufacturing will open up for a significant expansion of the Company’s market potential”, said Bredahl.
